Morgan Stanley analyst Zachary Sopcak said his is more bullish on Medidata Solutions (MDSO) coming out of ASCO saying it highlighted the company's leadership position as a technology provider to biopharma, how it will be a Pharma 3.0 enabler, and how it will continue to grow subscription growth by 20%+. Sopcak believes the Bristol-Myers Squibb (BMY) partnership more significant than appreciated and will help the company increase share with additional biopharma customers. The analyst reiterates his Overweight rating on Medidata and raised his price target to $56 from $51 on shares.